Feature | June 05, 2014

Siemens Announces First U.S. Installation of Symbia Intevo xSPECT System

June 5, 2014 — Fairview Health Services, Minneapolis, recently became the first U.S. healthcare facility to install the Symbia Intevo xSPECT system from Siemens Healthcare. The first ever xSPECT system, the Symbia Intevo fully integrates single-photon emission computed tomography (SPECT) and CT during image reconstruction, combining SPECT’s high sensitivity with the high specificity of CT and completely integrating data from the two modalities to generate high resolution and, for the first time, quantitative images.

“The Symbia Intevo’s ability to truly merge SPECT and CT data provides our physicians with invaluable additional diagnostic information, helping us to differentiate cancer from other forms of disease,” said Jerry Froelich, M.D., director of nuclear medicine and molecular imaging at the University of Minnesota. “For example, with the Intevo, we are better able to identify metastatic change within an area of degenerative change, such as the spine of older patients. The supporting information of the system’s xSPECT image enables us to make these kinds of objective interpretations of disease in cases where subjective interpretations had only been possible previously.”

The Symbia Intevo xSPECT system reconstructs both the SPECT and CT portions of the image into a much higher frame of reference than previous systems. The result is precise, accurate alignment of SPECT and CT that facilitates the extraction and deep integration of medically relevant information. This ability is also the basis for differentiating tissue boundaries in bone imaging. With xSPECT Bone, physicians can potentially provide additional support for detecting – and distinguishing between – cancerous lesions and degenerative disorders. In addition, single-step reading with integrated xSPECT Bone images may reduce physician time to read and report.

xSPECT Quant delivers precise alignment of SPECT and CT, providing physicians with essential volumetric information from the CT scan. This information enables accurate and consistent quantitative assessment – a numerical indication of a tumor’s level of metabolic activity. Accurate quantitative assessment enables the physician to assess whether a patient’s course of treatment has regressed, stabilized or grown.

The statements by Siemens customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption), there can be no guarantee that other customers will achieve the same results.

For more information: www.usa.siemens.com/healthcare

Related Content

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Cardiac MRI being performed at the DeBakey Heart Hospital.

Cardiac MRI being performed at the DeBakey Heart Hospital.

Feature | Cardiac Imaging | May 03, 2018 | By Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used...
Overlay Init